Compare Crispr Therapeutics AG (CRSP) vs Global Payments Inc (GPN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Global Payments Inc — how do they compare? Crispr Therapeutics AG trades at $50.93 (market cap $4.97B), while Global Payments Inc trades at $76.2 (market cap $20.76B). The key difference: Global Payments Inc is far larger — about 4.2× Crispr Therapeutics AG's market cap, and Global Payments Inc pays a 1.32% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | GPN | |
|---|---|---|
Market Cap | $4.97B | $20.76B |
Sector | Health | Industrials |
52-Week High | $76.78 | $90.01 |
52-Week Low | $44.34 | $62.47 |
Enterprise Value | $3.32B | $38.48B |
Dividend Yield | — | 1.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
GPN trades at $76.85, up 1.07% today, with a bullish technical signal from moving averages and recent earnings beats. The company reported Q1 2026 EPS of $2.96, exceeding expectations, and maintains strong cash flow from operations at $2.66B in 2025. However, net income margin turned negative at -7.97% for 2026, reflecting profitability challenges amid rising debt levels, with debt-to-asset ratio increasing to 41.57% in 2025.
The outlook is mixed: analyst consensus is bullish with a $81.56 price target and 58% buy ratings, supported by AI-driven POS expansions and the Worldpay integration. Key risks include margin pressure from fintech competition and high leverage, which could constrain equity returns if revenue growth falters.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Global Payments Inc
Global Payments is a leading provider of payment processing and software solutions and focuses on serving small and midsize merchants. The company operates in 30 countries and generates about one fourth of its revenue from outside North America, primarily in Europe and Asia. In 2019, Global Payments merged with Total System Services in an all-stock deal that gave Total System Services shareholders 48% of the combined company's shares.
Read more on GPN →
